Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results ...

ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, ...

And there were some additional revenues coming in that weren't anticipated originally that are part of this guidance. So... Pete Lawson Great, okay. Thank you so much. Thanks for the clarity. Operator Pete Lawson Kaveri Pohlman All right. That's helpful. And then my second question is regarding MGD-024. Any color on when you expect to complete the Phase I trial? And how much time Gilead will have to make a decision to opt in once you provide the data? Scott Koenig So with regard to 024, as I was commenting, ...

Exhibit 99.1 MacroGenics Provides Update on Corporate Progress and 2023 Financial Results ROCKVILLE, MD., Mar 7, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023. "We expect that 2024 will be an important year f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, INC. (Exact name of registrant) Delaware 06-1591613 (State of organization) (I.R.S. Employer Identification Number ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Conference Call Participants Good afternoon. We will begin the MacroGenics 2023 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions] At this point, I will turn the call over to Jim Karrels, Senior Vice President and Chief Financial Officer of MacroGenics. We would like to alert listeners that todayÂ's discussion will include statements about the companyÂ's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9704 Medical Center Drive Roc ...

MACRO GENICS® Corporate Update August 9, 2023 Cautionary Note on Forward-Looking Statements Legal Notices Trademarks Investigational Agents August 9, 2023 • Pursuing first-in-class targets 3 Multiple Platforms for Developing Innovative Biologics • Targeting improved efficacy and/or safety profile vs. traditional mAbs • Broad experience with CD3-directed bispecifics August 9, 2023 First-in-Human (Phase 1) Vobramitamab Duocarmazine (B7-H3) | --- | --- | --- | --- | --- | |--------------------------------|---- ...

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Jim Karrels - VP and CFO Scott Koenig - President and CEO Jonathan Chang - Leerink Partners Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Kaveri Pohlman - BTIG Yigal Nochomovitz - Citigroup Stephen Willey - Stifel Jon Miller - Evercore ISI Silvan Tuerkcan - JMP Securities Good afternoon. We will begin the MacroGenics 2023 Second Quarter Corporate Progress and Financial Results Conference Call in just a mo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of (I.R.S. ...